SEC Form 4 · accession 0001683168-26-006552
CNS Pharmaceuticals, Inc. · CNSP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Rami Levin
Officer — CEO and President
Period of report
Aug 14, 2026
Accepted (ET)
Aug 18, 2026 · 9:00 am EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001729427
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 14, 2026 | M | 4,750 | $0.00 | D | 4,750 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3,F2,F1 | — | Aug 14, 2026 | M | 4,750 | D | — | — | Common Stock | 4,750 | 14,250 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of Company common stock.
- F2On January 1, 2026, the reporting person was granted 19,000 restricted stock units, vesting as follows: 25% on the six-month anniversary of the grant date, 25% on the twelve-month anniversary of the grant date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date.
- F3Issued in connection with the reporting person's employment with the Company.